Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $35
Goldman Sachs analyst Graig Suvannavejh maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $31 to $35.
Related Posts
Aldeyra Therapeutics Sponsored Study Titled ‘An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease’ Posted To ClinicalTrials.gov; Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT05102409
